Icagen, Inc. Provides Update Regarding Clinical Development Plans for ICA-105665

April 27, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

RESEARCH TRIANGLE PARK, N.C., April 27, 2010 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today provided an update on clinical development plans for ICA-105665, the Company's novel drug candidate for the treatment of epilepsy and pain.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase II